The firm is an early-stage investment firm headquartered in Asia. The firm is actively seeking Seed through Series A opportunities and can invest up to approximately $3M over the lifecycle of a portfolio company. The firm evaluates opportunities across Asia, North America, and Europe and provides both financial and strategic support to emerging healthcare companies.
The firm invests broadly across life sciences, including therapeutics, medical devices, diagnostics, and digital health. The firm is indication-agnostic and seeks cutting-edge technologies addressing a wide range of healthcare needs. As an early-stage investor, the firm is comfortable evaluating technologies at the preclinical or early development stage and maintains a flexible approach to different technologies and business models.
From a company and management team perspective, the firm does not impose specific requirements. The firm can act as either a lead investor or co-investor, although the firm generally seeks a more active role and may prefer to lead when investing in very early-stage companies. Through relationships with healthcare organizations and strategic partners, the firm can also provide portfolio companies with operational, commercialization, and business development support.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 